⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SEPN News
Septerna, Inc. Common Stock
Protego Biopharma Appoints Jae B. Kim, MD, as Chief Medical Officer
prnewswire.com
AMGN
ALNY
SEPN
Form 8-K
sec.gov
SEPN
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results
globenewswire.com
SEPN
Septerna to Present at Bank of America Securities Health Care Conference
globenewswire.com
SEPN
Form 8-K
sec.gov
SEPN
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
globenewswire.com
SEPN
Form 8-K
sec.gov
SEPN
Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
SEPN
Form 8-K
sec.gov
SEPN
Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy
globenewswire.com
SEPN